--- title: "U.S. stock market midday update: Biovie up 9.62% on increased volume, no major positive drivers, intensified capital speculation" type: "News" locale: "en" url: "https://longbridge.com/en/news/294998509.md" description: "Biovie rose 9.62%; Amgen rose 4.16%, with a trading volume of USD 1.27 billion; Gilead Sciences fell 3.82%, with a trading volume of USD 853 million; AbbVie rose 0.74%, with a trading volume of USD 635 million; Forte Pharma rose 0.90%, with a market capitalization of USD 122.4 billion" datetime: "2026-08-05T17:53:36.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/294998509.md) - [en](https://longbridge.com/en/news/294998509.md) - [zh-HK](https://longbridge.com/zh-HK/news/294998509.md) generator: "portal-rs" --- # U.S. stock market midday update: Biovie up 9.62% on increased volume, no major positive drivers, intensified capital speculation **U.S. Stock Market Midday Update** Biovie, up 9.62%, with increased trading volume and no significant news recently. The trading is active, and the capital flow is evident. Considering the sector and industry trends, the stock shows significant volatility, and the specific reasons need further observation. **Stocks with High Trading Volume in the Industry** Amgen up 4.16%. Based on recent key news: 1. On August 5, Amgen announced its second-quarter financial report, with strong drug sales boosting the company's profits and raising its full-year expectations. The company reported quarterly profits of $2.38 billion, or earnings per share of $4.37, compared to $1.43 billion, or earnings per share of $2.65, in the same period last year. The adjusted earnings per share were $6.29, exceeding analysts' expectations of $5.62. Revenue increased from $9.18 billion in the same period last year to $10.05 billion, surpassing analysts' expectations of $9.43 billion. Source: Zhitong Finance 2. On August 5, Amgen announced the termination of the development of AMG 513 weight loss therapy but stated it would continue to track enrolled subjects. The company did not specify the reason for the termination. Source: Zhitong Finance 3. On August 5, Amgen raised its full-year performance guidance, expecting annual revenue between $38.2 billion and $39.4 billion, higher than the previous expectation of $37.1 billion to $38.5 billion. The adjusted earnings per share are expected to be between $22.30 and $23.50, higher than the previous range of $21.70 to $23.10. Source: Zhitong Finance The biotechnology industry is performing strongly, with significant capital inflow. Gilead Sciences down 3.82%. Based on recent key news: 1. On August 4, Gilead Sciences announced its second-quarter financial report, showing revenue growth to $7.8 billion, but a loss of $10.5 billion due to acquisition-related R&D expenses, putting pressure on the stock price. Source: Reuters 2. On August 3, the California Supreme Court ruled in favor of Gilead in the TDF lawsuit, which alleviated some legal risks for the company but failed to boost the stock price. Source: Reuters 3. On August 3, Gilead's CEO sold 15,000 shares of company stock, leading to negative market reactions to the executive's sell-off, causing the stock price to drop. Source: EDGAR HIV drug sales are strong, but sales of COVID-19 drugs are declining. AbbVie up 0.74%, with active trading. Based on recent key news: 1. On August 5, AbbVie announced the launch of a $10 billion bond issuance to fund the acquisition of Apogee Therapeutics. This move attracted about $63 billion in demand, showing market confidence in the deal and driving the stock price up. 2. On August 4, the FDA accepted AbbVie's application for a new indication for BOTOX Cosmetic, which, if approved, would become the only neurotoxin authorized to treat that symptom, enhancing market expectations for the company's future growth On August 3rd, AbbVie slightly lowered its earnings forecast for 2026, but its second-quarter performance exceeded expectations, mainly due to strong sales of immunology drugs, boosting investor confidence. The pharmaceutical industry is experiencing strong growth, and market confidence is increasing. **Stocks ranked among the top in industry market capitalization** Forte Pharma rose by 0.90%. Based on recent news, 1. On August 4th, Forte Pharma announced an adjusted earnings per share of $4.73 for the second quarter, exceeding analysts' expectations of $4.72, and raised its full-year revenue guidance to $13.1 billion - $13.2 billion, driving the stock price up. 2. On August 4th, Forte Pharma's total revenue for the second quarter reached $3.3 billion, a year-on-year increase of 12%, with strong performance in the cystic fibrosis business, and new products CASGEVY and JOURNAVX making significant contributions, further boosting market confidence. 3. On August 4th, Forte Pharma announced the acquisition of Crinetics Pharmaceuticals, with a transaction price of approximately $8.8 billion, expected to be completed in the third quarter. The acquisition news has enhanced investors' expectations for the company's future growth. The biotechnology sector is performing strongly, with high returns in the IPO market ### Related Stocks - [BIVI.US](https://longbridge.com/en/quote/BIVI.US.md) - [AMGN.US](https://longbridge.com/en/quote/AMGN.US.md) - [GILD.US](https://longbridge.com/en/quote/GILD.US.md) - [ABBV.US](https://longbridge.com/en/quote/ABBV.US.md) - [VRTX.US](https://longbridge.com/en/quote/VRTX.US.md) ## Related News & Research - [BioVie President and CEO Cuong V Do acquires 15,210 shares worth $31,637.68](https://longbridge.com/en/news/297376996.md) - [Joseph Palumbo Purchases 4,843 Shares of BioVie (NASDAQ:BIVI) Stock](https://longbridge.com/en/news/297401214.md) - [Dividend Aristocrat or Dividend Cuts: How to Evaluate the NKE Stock Payout as the Nike Turnaround Drags On](https://longbridge.com/en/news/296963043.md) - [Is Coca-Cola’s Q2 Beat And Upgraded Outlook Altering The Investment Case For KO?](https://longbridge.com/en/news/297406357.md) - [Jackson Hole Prediction Market Preview: What Will Kevin Warsh Say?](https://longbridge.com/en/news/297198524.md) --- > **Disclaimer: This article is for reference only and does not constitute any investment advice.**